Ponce Medical School Foundation Inc.

Ponce Medical School Foundation Inc., doing business as Ponce School of Medicine, is a tax-exempt nonprofit educational institution and Hispanic-serving minority institution headquartered in Ponce, Puerto Rico, that operates as a prime recipient on NIH and CDC federal grants focused on biomedical research and workforce training, with subordinate roles as a sub-recipient on research grants from university consortia partners. The institution does not hold federal contracts and competes exclusively in the grant funding space.

Ponce School of Medicine's federal footprint centers on NIH-funded biomedical research and doctoral training. Recent prime grants include a $751 thousand project grant from the National Institute for Minority Health and Health Disparities (CFDA 93.307) awarded September 1, 2026, to conduct the SMART-PREP randomized controlled trial evaluating virtually delivered mindfulness-based prenatal education for 300 pregnant individuals in Puerto Rico through February 2031. The institution also holds a $587 thousand T32 graduate training award from the National Institute of General Medical Sciences (CFDA 93.859) launched July 1, 2026, supporting 10 doctoral trainees annually in cancer biology, neuroscience, infectious disease, chronic disease modeling, and translational medicine through June 2031, with a placement goal of 75 percent of graduates in research-intensive roles within 12 months of graduation. Additional recent prime grants include a cooperative agreement from the National Center for Emerging and Zoonotic Infectious Diseases for the Puerto Rico Enhanced Surveillance and Control of Endemic and Emerging Arboviruses program (awarded September 1, 2025, through August 31, 2030), and NIH R01 project grants from the National Institute of General Medical Sciences and National Cancer Institute supporting investigator-initiated research in stress-induced fear extinction impairment in female rats (awarded August 1, 2025, through July 31, 2029), and trauma-cocaine use comorbidity mechanisms (awarded November 29, 2024, through June 30, 2025). A K08 mentored research career development grant from the National Cancer Institute (awarded August 1, 2024, through July 31, 2029) funds the CASA intervention pilot study for Latinx patients and caregivers with advanced cancer, and a cooperative agreement from the NIH Office of the Director (awarded September 20, 2023, through August 31, 2028) supports the Mental Health CPR multilevel community-based intervention addressing mental health disparities among Hispanic cancer survivors.

The institution's grant portfolio reflects heavy concentration in the National Institutes of Health system. The Department of Health and Human Services National Institutes of Health accounts for 21 awards in the recent portfolio, with 11 awards from the National Institute of General Medical Sciences and 9 from the National Cancer Institute. The Department of the Navy Bureau of Medicine and Surgery represents the largest customer by award count with 36 awards and $1.3 million combined potential value, though that concentration reflects educational and administrative payments rather than research funding. The Centers for Disease Control and Prevention places 8 awards. Across all 30 distinct customer agencies, 149 awards span prime and sub-recipient roles; combined potential value is $4.5 million, though obligated dollars ($338.6 million) substantially exceed potential value, indicating mature multi-year awards with significant prior invoicing.

Activity shows variable annual award volume: 5 awards in 2022, 7 in 2023, 13 in 2024, 6 in 2025, and 3 in 2026 to date. Four awards face ultimate completion within the next twenty-four months, presenting modest recompete exposure. The institution serves as prime on 125 awards (84%) and as sub-recipient on 24 awards (16%), with sub-award work flowing through university consortia including the University of Florida on vector-borne disease surveillance, Sloan-Kettering Institute for Cancer Research on cancer research training, the Henry M. Jackson Foundation on prostate cancer tissue collection from Hispanic patients in Puerto Rico, and Oregon Health and Science University on flavivirus immunogenicity and ovarian tumor immunology studies.

Ponce School of Medicine's research capability portfolio emphasizes minority health disparities, precision medicine for underrepresented populations, and Caribbean-anchored surveillance and epidemiology. The institution operates the Ponce Research Institute as its primary research infrastructure, staffed by faculty with active NIH funding records. Research focus areas include cancer health equity (triple-negative breast cancer in Caribbean Hispanic women, endometriosis mechanisms, prostate cancer in Puerto Rican men), neurobiology of trauma and substance use comorbidity, prenatal and perinatal health disparities in resource-constrained settings, and vector-borne disease surveillance and control in Puerto Rico, where the institution's geographic footprint and established clinical and community partnerships provide unique assets for studies enrolling Puerto Rican Hispanic populations. Workforce development programming leverages NIH training mechanisms (T32, R25, K08) to increase biomedical PhD completion and independent research career advancement among underrepresented minority students in an IDEA-eligible region.